K2M to Enter German Spine Marketplace

* Reuters is not responsible for the content in this press release.

Thu Nov 12, 2009 5:04pm EST

Smith & Nephew GMBH to distribute K2M Products
LEESBURG, Va.--(Business Wire)--
K2M, Inc., the spinal device company developing innovative and simplified
solutions for the treatment of complex spine pathologies and procedures, today
announced it has entered the German spine market through a distribution
arrangement with Smith & Nephew GMBH. 

"This announcement furthers K2M`s strategy of bringing its revolutionary
portfolio of spine products including the MESA® and DENALI® Spinal Systems,
RANGE® Spinal System, SERENGETI® Minimally Invasive Retractor System, CASPIAN™
Spinal System, and the ALEUTIAN® Interbody Systems to the global marketplace,"
said Eric Major, CEO and President of K2M. "We feel that a K2M, Inc. and Smith &
Nephew GMBH pairing provides the perfect combination of disruptive technology
and in-market expertise to best serve the complex and degenerative spinal
communities in the German market." 

Mark Augusti, the President of Spine & Biologics at Smith & Nephew stated,
"Smith & Nephew is already known in Germany for its innovative surgical spine
products and K2M`s exciting range of products will provide our customers with a
fully rounded portfolio. These differentiated technologies will allow surgeons
to address the most complex of spinal pathologies in addition to their
degenerative needs. We look forward to a successful relationship in Germany with
K2M beginning in earnest in 2010." 

The announcement marks the latest in a series of important international
accomplishments for K2M. Earlier this year, the company received PMDA approval
for its MESA Spinal System and began distributing its flagship product in Japan.
In addition to announcing the opening of a direct distribution office in the
United Kingdom in October, the company also recently entered the Austrian
marketplace. These new market launches supplement K2M`s existing international
activities in Spain, Mexico, Greece and Australia. "Developing a European base
is a clear statement that we are committed to expanding the global availability
of our innovative technology and to supporting surgeons treating the most
difficult of spinal pathologies," stated Christian Johnson, K2M`s European Vice
President. 

About K2M

K2M, Inc. is an innovative spinal device company committed to the research,
development, and commercialization of simplified solution for the treatment of
complex spinal pathologies and procedures. Chief Medical Officer, Chairman and
co-founder, Dr. John Kostuik, former Chief of Spine Surgery at The Johns Hopkins
University School of Medicine, drives K2M`s commitment to redefining the market.
The company is recognized as a worldwide leader in providing unique technologies
for the treatment of deformity, degenerative, trauma, and tumor spinal patients.
K2M`s complete portfolio of next generation products includes: spinal
stabilization systems, minimally invasive systems, and other advancing
technologies such as motion preservation, annular repair, and nucleus
replacement. Additional information is available online at www.K2M.com. 

About Smith & Nephew

Smith & Nephew is a global medical technology business, specializing in
Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy
and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy
and advanced wound management and is one of the leading global orthopaedics
companies. Smith & Nephew is dedicated to helping improve people`s lives. The
Company prides itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous with high
standards of performance, innovation and trust. The Company operates in 32
countries around the world. Annual sales in 2008 were $3.8 billion.

K2M, Inc.
Lane Major, VP of Marketing
703-777-3155 ext. 264
lmajor@K2M.com

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.